Form 4: Precigen COO Rutul R. Shah Receives Equity Grant

Precigen COO Rutul R. Shah was granted 395,000 stock options and 118,000 restricted stock units on April 20, 2026.

Summary

• Rutul R. Shah, Chief Operating Officer of Precigen, Inc., received a new equity compensation package.
• The grant includes 395,000 stock options with an exercise price of $4.11 per share.
• The grant also includes 118,000 restricted stock units (RSUs), each representing a right to one share of common stock.
• Both the options and RSUs follow a multi-year vesting schedule beginning in May 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is standard practice and does not signal a change in company strategy or financial health.

Positives

• Equity grants align the interests of the COO with long-term shareholder value creation.
• The multi-year vesting schedule (four years) serves as a retention mechanism for key executive talent.

Negatives

• The issuance of new equity awards results in potential future dilution for existing shareholders.

Risks

• The value of the granted equity is subject to market volatility and the future performance of Precigen common stock.
• Vesting is contingent upon continued employment, creating potential turnover risk if the executive departs before the full vesting period.

Future Outlook

The equity grants are structured to incentivize long-term performance, with vesting occurring over a four-year period ending in 2031.

Management Comments

• The filing does not contain narrative management commentary.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard for aligning executive incentives in the biotechnology sector, where long-term R&D cycles necessitate high retention of leadership.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The use of a mix of stock options and RSUs is a common compensation strategy used by peers such as Intellia Therapeutics or CRISPR Therapeutics to balance risk and reward.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and settlement of these equity awards.

Next Steps

• Vesting of 25% of the options and RSUs on May 23, 2027.
• Continued monthly/six-month vesting installments through 2031.

Key Dates

Keywords

Precigen, PGEN, Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Insider Transaction